20Sep 2021
Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer

The efficacy and safety of trastuzumab deruxtecan (formerly DS-8201), a HER2 antibody–drug conjugate, in patients with HER2-mutant NSCLC have not been investigated extensively. Trastuzumab deruxtecan showed durable anticancer activity in patients with previously treated HER2-mutant NSCLC. The safety profile included interstitial lung disease that was fatal in two cases. Observed toxic effects were generally consistent with those in previously reported studies.

  • #family health

Like

Save

Share